- Home
- ENGN vs TLSA Comparison
ENGN vs TLSA Comparison
Compare ENGN & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGN
- TLSA
- Stock Information
- Founded
- ENGN 1999
- TLSA 2013
- Country
- ENGN Canada
- TLSA United Kingdom
- Employees
- ENGN N/A
- TLSA N/A
- Industry
- ENGN
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- ENGN
- TLSA Health Care
- Exchange
- ENGN Nasdaq
- TLSA Nasdaq
- Market Cap
- ENGN 191.1M
- TLSA 187.0M
- IPO Year
- ENGN N/A
- TLSA 2000
- Fundamental
- Price
- ENGN $3.83
- TLSA $2.38
- Analyst Decision
- ENGN Buy
- TLSA
- Analyst Count
- ENGN 7
- TLSA 0
- Target Price
- ENGN $23.29
- TLSA N/A
- AVG Volume (30 Days)
- ENGN 94.6K
- TLSA 341.1K
- Earning Date
- ENGN 09-09-2025
- TLSA 08-12-2025
- Dividend Yield
- ENGN N/A
- TLSA N/A
- EPS Growth
- ENGN N/A
- TLSA N/A
- EPS
- ENGN N/A
- TLSA N/A
- Revenue
- ENGN N/A
- TLSA N/A
- Revenue This Year
- ENGN N/A
- TLSA N/A
- Revenue Next Year
- ENGN N/A
- TLSA N/A
- P/E Ratio
- ENGN N/A
- TLSA N/A
- Revenue Growth
- ENGN N/A
- TLSA N/A
- 52 Week Low
- ENGN $2.65
- TLSA $0.63
- 52 Week High
- ENGN $11.00
- TLSA $2.76
- Technical
- Relative Strength Index (RSI)
- ENGN 56.57
- TLSA 77.08
- Support Level
- ENGN $3.45
- TLSA $1.62
- Resistance Level
- ENGN $3.94
- TLSA $1.89
- Average True Range (ATR)
- ENGN 0.27
- TLSA 0.18
- MACD
- ENGN 0.00
- TLSA 0.09
- Stochastic Oscillator
- ENGN 76.06
- TLSA 81.20
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.